Intravenous lipid emulsion is, in some countries, the recommended treatment for local anaesthetic toxicity. Systemic local anaesthetic toxicity results in hypoxaemia and acidosis, and whether this influences the effects of lipid therapy on drug concentrations and cardiovascular recovery is currently unknown. Twenty anaesthetised pigs were given a 3 mg/kg bolus of levobupivacaine followed by a five-minute phase of hypoventilation and 1 mmol/kg of lactic acid over one minute. After lactic acid infusion, pigs were treated, in randomised order, with either 20% lipid emulsion or Ringer's acetate for 30 minutes: a 1.5 ml/kg bolus followed by a 0.25 ml/kg/minute infusion. Haemodynamic parameters were recorded and blood samples were collected for pharmacokinetic analysis. There was no difference between the groups in the area under the plasma levobupivacaine concentration-time curve (AUC) or between that and AUC of unentrapped levobupivacaine in the Lipid group, or in the plasma half-lives. The cardiovascular outcome and normalisation of the electrocardiogram were similar in both groups. Five pigs developed marked hypotension: one in both groups died, while two in the Lipid group and one in the Ringer group needed adrenaline. Administration of lipid emulsion did not improve cardiovascular recovery from levobupivacaine toxicity exacerbated by acidosis and hypoxaemia. Lipid emulsion did not entrap levobupivacaine or affect levobupivacaine pharmacokinetics.
Large-scale surveys in the last 15 years indicate that the incidence of seizures associated with regional anaesthesia varies from 0.6 to 3.5 per 10,000 [1] [2] [3] . Compiled data of these three surveys (395,105 regional anaesthesias) revealed that the incidence of severe cardiac toxicity was as low as 0.05 per 10,000. Intravenous (IV) lipid emulsion (lipid rescue) has been recommended as adjunct therapy in severe systemic local anaesthetic toxicity (LAST) 4 . Most case reports and experimental animal studies on the use of intravenous lipid emulsion describe successful outcome after local anaesthetic-induced cardiovascular collapse, or cardiac arrest [5] [6] . Lipid emulsion may also be effective for aborting local anaesthetic-induced central nervous system (CNS) toxicity symptoms 7, 8 as well as for preventing the progression of toxicity to the heart 9, 10 . The potential mechanisms of action of intravenous lipid emulsion on local anaestheticinduced CNS symptoms include entrapment of the drug to the lipid phase in plasma (lipid sink) and a pharmacokinetic effect (enhanced distribution) 11, 12 .
Animal model studies on lipid rescue have usually been performed under normal acid-base balance and normoxia 5, 13, 14 . However, severe seizures associated with LAST induce marked acute pathophysiological disturbances, e.g., acidosis and hypoxia [15] [16] . Untreated severe acidosis may aggravate the toxic action of bupivacaine due to reduced binding to plasma proteins 17 , as well as enhanced intracellular ionisation of the drug 18 . Hypoxaemia, on the other hand, worsens both CNS and cardiovascular toxicity of bupivacaine [19] [20] .
In the present animal model study, we included acute lactic acidosis, respiratory acidosis and hypoxaemia in order to simulate the immediate consequences of severe local anaesthetic-induced seizures, and studied whether intravenous lipid emulsion exhibits a lipid rescue effect in acute levobupivacaine toxicity. The higher free unionised bupivacaine concentration after acidosis should increase entrapment of bupivacaine in the lipid sink due to the higher concentration gradient between the plasma and lipid compartments.
Methods
These experiments were conducted in the Research and Development Unit of the Helsinki University Hospital. The protocol was approved by the National Animal Experiment Board (ESAVI/5027/04.10.07/2014; Hämeenlinna, Finland).
Experimental protocol
Twenty Landrace pigs (range 21-29 kg, age approximately three months) were anaesthetised with isoflurane. The animals were then placed on a warming mattress under an external radiant heater to keep the oesophageal temperature in the range of 37.5-39.0°C. After tracheal intubation, the animals were mechanically ventilated with 2% isoflurane (end-tidal) in 21% oxygen (Servo Ventilator 900C; Siemens-Elema, Solna, Sweden). The minute volume was adjusted to keep the endtidal CO 2 concentration in the range 5.0%-5.5% at a fixed rate of 20 breaths per minute. Catheters were inserted into the femoral artery, the internal jugular vein and peripheral veins of both ears. A maintenance fluid infusion (Ringer's acetate) was administered at a rate set to keep central venous pressure above 2 mmHg. The arterial and central venous blood pressures, fivelead electrocardiogram (ECG), and peripheral oxygen saturation were continuously monitored (Datex-Ohmeda Division; Instrumentarium Corp, Helsinki, Finland) and stored digitally (iCentral® and S/5 Collect®; GE Health Care, Helsinki, Finland).
Our experimental protocol is presented in Figure 1 . Five to 10 minutes before starting levobupivacaine administration the pigs were paralysed using a bolus of pancuronium bromide 4 mg IV (Pancuronium-Actavis® 2 mg/ml; Actavis Group PTC ehf., Hafnarfjörður, Iceland). Levobupivacaine 3 mg/kg (Chirocaine® 7.5 mg/ml; AbbVie Oy, Espoo, Finland) was injected into the jugular vein over 20 seconds. The minute ventilation was reduced by 30% immediately after the administration of levobupivacaine for five minutes to produce hypercapnia. One minute after the levobupivacaine bolus, lactic acid 1 mmol/kg (LD-Lactic acid 90% [T]; Sigma-Aldrich Co., St. Louis, MO, USA; diluted to 4 mmol/ml with 0.9% saline) was infused over one minute to produce metabolic acidosis. Immediately after the lactic acid infusion, the pigs received one of the treatment fluids, either lipid emulsion (Lipid group; Intralipid® 20%; Fresenius Kabi AB, Uppsala, Sweden) or Ringer's acetate solution (Ringer group; Ringer-Acetate Baxter Viaflo®; Baxter Medical, Kista, Sweden) in a randomised order (allocation using sealed envelopes): 1.5 ml/kg IV over one minute followed by a 0.25 ml/kg/ minute infusion for 29 minutes. Five minutes after the levobupivacaine bolus, minute ventilation was normalised and inspired oxygen was raised to 100% for the remaining time of the treatment infusion, after which it was decreased back to 21%. If mean arterial pressure (MAP) decreased below 25 mmHg, the pigs were given adrenaline 0.25 mg IV, repeated after one minute if hypotension persisted. External chest compression and defibrillation were performed if needed. The levobupivacaine dose of 3 mg/kg was chosen as in pilot studies; higher doses of levobupivacaine (followed by acidosis) resulted in refractory cardiac arrest.
Blood gas analysis and levobupivacaine concentration measurement
Arterial blood gas analyses (ABL800 FLEX; Radiometer Medical ApS, Copenhagen, Denmark) were made from samples collected at baseline, at the end of lactic acid infusion, and 3, 5 and 60 minutes after the start of treatment. Arterial blood samples for levobupivacaine concentration measurement were collected into heparinised tubes at baseline, at the time when the levobupivacaine dose had been given, and 5, 10, 20, 30, 45 and 60 minutes after start After anaesthesia and preparations, the pigs were randomised into either Lipid or Ringer group (10 pigs in each group). Levobupivacaine 3 mg/kg was administered over 20 seconds. Lactic acid (Lac) was then infused 1 mmol/kg over one minute. Treatment (lipid emulsion or Ringer) solutions were administered as 1.5 ml/kg bolus over one minute followed by 0.25 ml/kg/minute infusion until 30 minutes.
of treatment. At the end of the experiment (60 minutes after the beginning of treatment), the pigs were sacrificed with an IV bolus of potassium chloride concentrate. The blood samples were centrifuged at 2,500 g for ten minutes to separate the plasma, which was then stored at -22°C. Bupivacaine is stable for at least six months when stored below -17°C 21 ; the samples were analysed within that time period. After storage, the samples were analysed in one session. Aliquots of the plasma of the pigs in the Lipid group were further centrifuged twice at 20,800 g for 10 minutes to separate the lipid fraction. Then aliquots of the lipidpoor plasma were taken for determination of unentrapped (non-lipid-bound) levobupivacaine concentration. Plasma levobupivacaine concentrations were determined using a previously described method 22 in the laboratory of the Department of Clinical Pharmacology of University of Helsinki using an Agilent 1100 HPLC (Agilent Technologies, Waldbronn, Germany) coupled to an API 2000 high-performance liquid chromatography-tandem mass spectrometry system (Sciex Division of MDS Inc., Toronto, ON, Canada) with ropivacaine as an internal standard. The limit of detection of the assay was 0.01 mg/l and the linear dynamic range was 0-30 mg/l. The mean inter-day coefficients of variation were 5.4%, 4.5% and 6.9% at 24, 7.5 and 0.75 mg/l concentrations, respectively.
Data analysis and statistics
Levobupivacaine pharmacokinetics were analysed by calculating the area under the concentration-time curve from 0 to 60 minutes (AUC 0-60 min ) and the estimation of its plasma half-life (T 1/2 ). The AUC 0-60 min of levobupivacaine was calculated using the linear trapezoidal rule while the T 1/2 of levobupivacaine was determined using non-linear regression. The baseline width of the QRS complex was calculated separately for each pig as a mean of five consecutive complexes at baseline. After levobupivacaine, the QRS width was considered normal when it narrowed to within two standard deviations (SD) of the baseline mean.
The pharmacokinetic variables, arterial pH, arterial base excess (BE), arterial lactate concentration, MAP, heart rate, PQ interval, QRS width, and QTc interval were compared using the Student's t-test. Non-normally distributed oxygen saturation, time for normalisation of QRS width, and percent change of T wave height were compared using the Mann-Whitney U test. The statistical significance level was set at 0.05, and the Holm-Sidak method was used to correct for multiple comparisons. All statistical analyses were performed using Prism 6.0f for Mac OS X (GraphPad Software, Inc., La Jolla, CA, USA). We defined a 20% difference in levobupivacaine concentration as therapeutically significant 23 . At a significance level of 0.05, a study with ten animals per group was estimated to yield a power of 83%.
Results
At baseline, MAP was slightly higher in the Lipid group than in the Ringer group (Figure 2 ; P=0.02). Otherwise, neither baseline nor 0 minute timepoint (beginning of rescue infusion) haemodynamic values or ECG parameters differed between the study groups. One pig in each group died after the end of lactic acid infusion in spite of resuscitation attempts; their levobupivacaine plasma concentrations just after the end of the levobupivacaine bolus were 38.9 and 25.5 mg/l, i.e. within the range of that of the other pigs. The ECG data of one pig in the Lipid group could not be analysed due to technical problems. Two pigs in the Lipid group developed a mild skin rash soon after the start of the lipid emulsion infusion while two other pigs in the Lipid group developed a visible mild rash near the end of the 30-minute lipid emulsion administration. The skin rashes were not associated with cardiovascular collapse. By the end of the experiment, 30 minutes after finishing the lipid infusion, no rash was visible in any of these pigs.
ECG, haemodynamics and peripheral oxygen saturation
The ECG showed an equal lengthening in cardiac conduction times during the intoxication phase, especially in QRS width (Table 1 ). There was also no difference in median (interquartile range) time to normalisation of QRS width to baseline: 245 seconds (198-477 seconds) in the Lipid group and 245 At the baseline (B) the mean arterial pressure ( Figure A) was higher in the Lipid group than in the Ringer group (P=0.02). At the beginning of rescue infusions or other timepoints there were no differences between groups. Heart rate ( Figure B ) did not differ between the groups at any timepoint. L, levobupivacaine administration.
seconds (165-382 seconds) in the Ringer group (P=0.59).
In most pigs, the mean MAP ( Figure 2 ) remained stable after the levobupivacaine and lactic acid infusion except in four pigs (two in each group) who developed marked hypotension (in addition to those two could not be resuscitated). Three of those (two in the Lipid group and one in the Ringer group) were given adrenaline IV to prevent cardiac arrest as their MAP decreased below 25 mmHg. To exclude the effect of adrenaline, those pigs were excluded from haemodynamic analyses at timepoints three and five minutes. The arterial blood pressure increased markedly in both groups after the beginning of treatment but there was no difference in peak MAP after treatment solution boluses between the groups (mean [SD] 93 [16] mmHg in the Lipid group and 82 [26] mmHg in the Ringer group, P=0.34) or at any later timepoint.
The mean heart rate ( Figure 2 ) decreased slightly in both groups after the levobupivacaine bolus but then increased rapidly during the lactic acid infusion, being highest at the end of the hypoventilation period (i.e. three minutes after the start of rescue infusion). It returned to baseline within ten minutes in both groups and there were no differences between groups at any timepoint.
Peripheral oxygen saturation decreased after the start of hypoventilation being at the lowest below 75% in both groups by the end of the hypoventilation period after which it normalised rapidly. Saturation did not differ at any timepoint between the groups.
The mean (SD, range) peak levobupivacaine concentration (C max ) was 35.3 (4.6, 29.0-43.2) mg/l in the Lipid group and 36.3 (11.7, 27.6-41.2) mg/l in the Ringer group (P=0.81), after which it decreased rapidly (Figure 3 ). From five minutes on, the total plasma levobupivacaine concentration decreased with a mean (SD) plasma T 1/2 of 52.2 (10.8) minutes in the Lipid group and 57.4 (9.4) minutes in the Ringer group (P=0.30). The mean (SD) AUC 0-60 min of total levobupivacaine was similar in both groups: 384.4 (92.6) mg.min/l in the Lipid group and 346.5 (59.7) mg.min/l in the Ringer group (P=0.32). The mean (SD) AUC 0-60 min of unentrapped levobupivacaine plasma concentration in the Lipid group was 383.0 (95.0) mg.min/l, i.e. similar to that of plasma total levobupivacaine concentration (P=0.67).
Arterial blood gases
All pigs developed hypoxaemia (decreased peripheral oxygen saturation) and hypercapnia (increased end-tidal CO 2 ) during the phase of hypoventilation and IV infusion of lactic acid (Table 2) . At the end of lactic acid infusion, the blood gas analyses showed severe respiratory and metabolic acidosis (mean pH 7.07 in the Lipid group and pH 7.08 in the Ringer group), and a significant rise in lactate blood concentrations (Figure 4) . The acid-base balance began to improve within minutes after the end of lactic acid infusion. The return towards normal pH was faster in the Ringer group (Table 2 ; P <0.005). However, BE, and after statistical correction for multiple comparisons, lactate or PaCO 2 did not differ at any timepoint.
Discussion
In the present study, the cardiovascular recovery from levobupivacaine systemic toxicity aggravated by concomitant acidosis and hypoxaemia was similar using rescue infusion Figure 3 . Plasma levobupivacaine concentrations.
The peak levobupivacaine concentration or the area under the concentration-time curve did not differ between the groups. Lipid emulsion also did not entrap levobupivacaine. L, levobupivacaine administration. with a recommended dose of lipid or a corresponding dose of Ringer's acetate. There was no difference in normalisation of ECG, arterial blood pressure or heart rate between groups. The pharmacokinetics of levobupivacaine were similar in both groups. The plasma levobupivacaine concentration in the present study was approximately 35 mg/l at its highest, which is considerably above the lowest concentration (2.6 mg/l) known to cause mild central nervous system and cardiac effects in humans 24 . This suggests that the levobupivacaine dose we used would likely have caused severe symptoms such as seizures in patients. Also, the severe acidosis in our study resembles very closely a clinical situation in which acidosis develops as a result of severe seizures due to systemic local anaesthetic toxicity 16 . There are at least two major reasons why this kind of acidosis worsens the cardiotoxicity of local anaesthetics: one is iontrapping into the cardiac tissue 25 and another is decreased binding of the compound in blood allowing enhanced tissue uptake 26 , and consequently increased binding of the local anaesthetic to sodium channels 19 . The decreased first-pass lung uptake of local anaesthetics because of acidosis, experimentally shown in rabbits 27 , may be a third separate mechanism of enhanced toxicity.
There was no indication of a major lipid sink mechanism of action in plasma since the AUC 0-60 min of levobupivacaine total concentration was similar to that of unentrapped levobupivacaine concentration. This is in accordance with results from our previous studies with bupivacaine in the same pig model without metabolic and respiratory acidosis 14 .
In the present study, no support for a possible beneficial pharmacokinetic mechanism of action by lipid in levobupivacaine toxicity was seen. In our own previous study, lipid infusion shortened the plasma T 1/2 of plasma bupivacaine in human volunteers 28 . The possible reason for the lack of effect on T 1/2 in the present study can likely be found from the differences in intoxication protocols. In the human volunteers the mean maximum plasma bupivacaine concentration was 0.61 mg/l after a 20 minute infusion, and in pigs the mean maximum plasma levobupivacaine concentration was 35.3 mg/l two minutes before lipid treatment. In the higher intoxication range, achieved in the present study, the significantly reduced and variable protein binding of bupivacaine in plasma 25 , and the concomitantly depressed cardiovascular function will influence bupivacaine pharmacokinetic parameters.
Our result showed a small, but statistically significant, difference in arterial pH between the groups soon after the start of the rescue infusions (Figure 4) . The slightly lower pH in the Lipid group, i.e. a mean difference of 0.09 and 0.07 at three and five minutes, respectively, may be primarily due to higher mean PaCO 2 values at the same timepoints with a possible additive influence of the slightly higher mean lactate value obtained at the three minute measuring timepoint ( Table 2 ). An influence on the blood gas measurements of the pH of Intralipid (pH approximately 8) 29 and Ringer's acetate (pH 5-6) 30 can probably be neglected since the infused volume in the first five minute period represents only about 5% of the pig's plasma volume.
As we could not show any rescue potential of lipid regarding haemodynamic parameters, it is possible that the clinically recommended dose of lipid which we used, (1.5 ml/kg over one minute followed by infusion) 4 is too small to improve cardiovascular recovery when compared with Ringer's acetate. The most convincing studies on lipid rescue have been carried out in rodents with much higher doses (4 to 9 ml/kg in 20 to 60 seconds) 13, 31, 32 . The higher lipid emulsion dose has also improved survival from severe local anaesthetic cardiac toxicity in piglets, but the most important treatment seems to be administration of adrenaline which improves survival when compared to lipid emulsion 34 . The combination of lipid emulsion with adrenaline may be even more effective than either treatment alone, even though the slight differences between the groups have not reached statistically significant difference 33, 35 . From a practical point of view, however, a large bolus dose equalling those given to rodents (up to 10 ml/kg in one minute) would be impossible to inject rapidly through a peripheral 18-22G venous cannula in patients. Therefore, dose-dependence studies to find the realistic, optimal and safe lipid rescue dose in man may be required.
The enhancement of levobupivacaine toxicity by acidosis and hypoxaemia in the present study remains an assumption since we did not include any normal acid-base balance controls. Udelsmann et al 36 reported no mortality, nor need for IV adrenaline, to treat severe hypotension after a rapid IV injection of 4 mg/kg levobupivacaine in anaesthetised pigs. Thus, the more severe haemodynamic outcome after 3 mg/kg levobupivacaine combined with acidosis and hypoxaemia in our anaesthetised pigs suggests clear exacerbation of the cardiotoxic effect of levobupivacaine.
In our study, four pigs developed a mild reddish skin rash during lipid infusion, but in comparison with the Ringer group these pigs had no particular haemodynamic instability during the rescue infusion. Experimental lipid emulsion studies in pigs have been criticised because among the animal species usually employed in medical research, the pig might be prone to develop a complement-related hypersensitivity reaction 37 . A recent study showed that large lipid doses (5 ml/kg bolus following a 1.5 ml/kg bolus = 6.5 ml/kg) may cause severe cardiovascular disturbances and visible skin rash in pigs, but complement activation could not be demonstrated 38 . However, the currently recommended lipid emulsion dosage does not seem to produce adverse cardiovascular effects in pigs 14, 34, 39 . The pig is physiologically and anatomically closer to humans than rodents, and as the drug metabolic pathways are quite similar to humans, the pig is considered a very suitable model, possibly even better than many other large mammals, for toxicological research 40 .
General anaesthesia may be considered a confounding factor in studies on LAST since general anaesthetics may protect the heart against a hypoxic or toxic insult 41 . It was shown in ewes that after comparable IV doses of local anaesthetics, cardiovascular fatalities occurred only in conscious animals and not in animals anaesthetised with halothane or isoflurane 42 . In the present study, however, the end-tidal isoflurane was kept at a standardised concentration of 2.0+/-0.1% in both groups during the study.
Conclusions
There was no difference in cardiovascular recovery after a recommended rescue infusion of intravenous lipid emulsion compared to Ringer´s acetate in this animal model of levobupivacaine systemic toxicity, which includes lactic and respiratory acidosis and hypoxaemia. In addition, there was no enhanced entrapment of levobupivacaine in plasma by lipid in the initial phase of acidosis or during return to normal acid-base balance. The lack of difference in plasma T 1/2 and AUC 0-60 min between the groups indicated no influence of lipid on levobupivacaine distribution.
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